Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Jean-Luc Vachiéry

    Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium

    Prof. Jean-Luc Vachiéry is a clinical professor of cardiology and director of the Pulmonary Vascular Diseases and Heart Failure Clinic at the Hôpital Universitaire de Bruxelles Erasme in Belgium. read more

    He received his board certification in Internal Medicine in 1992 and in Cardiology in 1995. He has authored several articles and book chapters, and participated in many collaborative research projects in the field of pulmonary hypertension. This led to the creation of a clinical unit dedicated to patient management and clinical research in pulmonary hypertension and heart failure in 2008.

    Prof. Vachiéry has co-chaired the Pulmonary Hypertension Council at the International Heart and Lung Society (2002–2005), the Working Group on Pulmonary Circulation and Right Ventricular Function at the European Society of Cardiology (ESC; 2006–2008) and the Working Group on Heart Failure at the Belgian Society of Cardiology (2008–2010). He was a Task Force member and section lead of the European Guidelines on Pulmonary Hypertension (2009, 2015 and 2022). Prof. Vachiéry has chaired the Peripheral Vascular Disease Interdisciplinary Network at the International Society for Heart and Lung Transplantation (ISHLT; 2018–2020) and was chair of the Cardiology Professional Community at the ISHLT (2022–2024). He was a member of the Nucleus Working Group on Right Ventricular Failure and Pulmonary Hypertension at the ESC from 2008 to 2024.

    Prof. Vachiéry was a member of the World Symposium on Pulmonary Hypertension in 2003 (Transplantation and Atrial Septostomy) Task Force and co-chair of the Pulmonary Hypertension Due to Heart and Lung Diseases Task Force in 2013. He chaired the Task Force on Pulmonary Hypertension Due to Left Heart Diseases (PH-LHD) in 2018 and was senior adviser to the PH-LHD Task Force in 2024. He is a member of the scientific steering committee of the World Symposium on Pulmonary Hypertension Association.

    Prof. Vachiéry’s centre is a founding member of the European Reference Network – Lung, Pulmonary Hypertension, where he is part of the Research and Guidelines subcommittee. He acts as an expert for several regulatory agencies and scientific organizations for matters related to medicines and care of pulmonary hypertension.

    Prof. Jean-Luc Vachiéry Discloses: Advisory Board or Panel fees from Acceleron (relationship terminated), Aerovate, Bayer HealthCare (relationship terminated), Boehringer Ingelheim, Enzyvant (now Sumitomo Dainippon Pharma; relationship terminated), Gossamer Bio, Insmed, Janssen, Liquidia and Merck/MSD. Consultancy fees from Acceleron (relationship terminated), Bayer HealthCare (relationship terminated), Gossamer Bio, Insmed, Janssen, Keros, Liquidia and Merck/MSD.
    Prof. Manreet Kanwar

    Allegheny General Hospital, Pittsburgh, PA, USA

    Professor Manreet Kanwar is the medical director of the Mechanical Circulatory Support and Cardiac Transplant Program and the co-director of the Division of Heart Failure and Pulmonary Hypertension at Allegheny General Hospital (AGH) in Pittsburgh, PA, US.read more

    Prof. Kanwar is an advanced heart failure physician with expertise in the management of patients with cardiogenic shock, end stage heart failure, mechanical circulatory support and pulmonary hypertension. A dedicated researcher with over 130 peer reviewed articles, she has conducted several clinical trials as primary investigator in the field of heart failure and pulmonary hypertension. Her research career is focused on the art of decision making using artificial intelligence and machine learning. She was elected to the board of directors for the International Society of Heart and Lung Transplantation and serves on the editorial board for the Journal of Heart and Lung Transplantation. Prof. Kanwar was named as one of Pittsburgh Magazine’s “Best Doctors” in 2019–2024.

    Prof. Manreet Kanwar Discloses: Advisory Board or Panel fees from Abbott and Abiomed. Consultancy fees from Bivacor. Speaker’s Bureau fees from Abiomed.
    touchRESPIRATORY touchRESPIRATORY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Pulmonary Hypertension

    US PULMONARY HYPERTENSION PARTNER

    An Introduction to Pulmonary Hypertension

    With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape

    Our supporting partners do not constitute an endorsement of the content on this page.

    Pulmonary Hypertension Content

    Pulmonary Hypertension, Rare Diseases
    Watch Time: 34 mins
    touchIN CONVERSATION
    Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment
    CE/CME ACCREDITED Prof. Jean-Luc Vachiéry, Prof. Manreet Kanwar Translations available:

    Watch two experts discuss the diagnosis, risk stratification and treatment of pulmonary arterial hypertension.

    Learning objectives
    Learning Objectives
    • Outline the clinical features of PAH and the steps to diagnosis
    • Recognize the importance of risk stratification of patients with PAH to optimize treatment management
    • Apply current guideline-recommended treatment algorithms and emerging therapeutic agents for PAH
    Asthma, COPD, Pulmonary Hypertension, Sleep Related Breathing Disorders, Lung Health
    United for a breathable future: A message from Irina Petrache, MD, ATSF, President of the American Thoracic Society on World Lung Day

    As we observe World Lung Day, it is crucial to reflect on the escalating impact of respiratory diseases across the globe. Chronic respiratory diseases — including chronic obstructive pulmonary disease (COPD), asthma, lung cancer, pulmonary hypertension, obstructive sleep apnea, and others — continue to rank among the leading causes of morbidity and mortality worldwide. The World Health Organization’s latest data underscores the persistence of the global respiratory crisis:

    Pulmonary Hypertension
    Watch Time: 33 mins
    touchEXPERT OPINIONS
    Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach
    CE/CME ACCREDITED Prof. Harrison Farber, Prof. Marion Delcroix, Prof. Stephan Rosenkranz

    Watch three experts share their perspectives and best-practice guidance on how to optimize the diagnosis and management of pulmonary arterial hypertension (PAH).

    Learning objectives
    Learning Objectives
    • Recognize the importance of early diagnosis and rapid classification of PAH
    • Discuss the setting of effective treatment goals and implementing appropriate therapeutic strategies
    • Evaluate the data for emerging therapies and strategies for improving quality of life for patients with PAH
    Pulmonary Embolism, Pulmonary Hypertension, Sleep Related Breathing Disorders
    Foreword touchREVIEWS in Respiratory & Pulmonary Diseases Volume 7, Issue 2, 2022

    touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):31

    Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases, which covers several hot topics in respiratory medicine, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, bronchiectasis and the ever-present subject of Coronavirus Disease 2019 (COVID-19). The articles and expert opinions in this journal reflect the progress and challenges in this active […]

    Interstitial Lung Disease, Pulmonary Hypertension
    Developed by Touch
    Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
    Watch Time: 6 mins

    INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]

    Pulmonary Hypertension
    Developed by Touch
    Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
    Watch Time: 5 mins

    INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]

    Pulmonary Hypertension
    Developed by Touch
    Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
    Watch Time: 2 mins

    LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]

    Pulmonary Hypertension
    Developed by Touch
    Gustavo Heresi, PHA 2022: Chronic Thromboembolic Pulmonary Hypertension
    Watch Time: 3 mins

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels in the lungs. The characteristics and challenges of diagnosing CTPEH are discussed in this touchRESPIRATORY interview […]

    Pulmonary Hypertension
    Developed by Touch
    Gustavo Heresi, PHA 2022: Treatment Options and Emerging Therapies for Chronic Thromboembolic Pulmonary Hypertension
    Watch Time: 5 mins

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels in the lungs. The surgical and medical treatment options for CTEPH and their limitations are discussed […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchRESPIRATORY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup